DuoCort Pharma and Recipharm start collaboration for the treatment of Addison’s disease
DuoCort Pharma announces it has concluded an agreement with Recipharm under which Recipharm is set to scale-up the manufacturing of DuoCort’s tablets to commercial scale as DuoCort Pharma prepares for market entry with its orphan drug for the treatment of Addison’s disease. The scale-up agreement represents a risk sharing collaboration in which Recipharm will co-invest in the scale-up along with DuoCort Pharma.
DuoCort Pharma, took a step closer to the market earlier this year when it filed for marketing authorisation in the EU for its new treatment for the rare and life threatening disease adrenal insufficiency, often referred to as Addison’s disease.
Although cortisol replacement therapy for adrenal insufficiency has been around for a long time, several studies have recorded premature death, impaired quality of life, increased risk of cardiovascular diseases and decreased bone mineral density in these patients. Existing replacement therapies, unable to mimic cortisol’s normal diurnal release profiles, are viewed as the likely cause of these outcomes. The new treatment from DuoCort Pharma has a physiological release profile which mimics the body’s natural release of cortisol, thereby improving treatment outcomes.
Other news from the department business & finance
